Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares increased 5.62 percent to close at $6.01 a share Thursday. The stock traded between $5.90 and $6.15 on volume of 1.84 million shares traded. Analysts at Wells Fargo have recently initiated coverage on the company with an “outperform” rating.
Find out more about BioCryst Pharmaceuticals including full access to the free equity report at:
Santarus, Inc. (NASDAQ: SNTS) shares declined 4.28 percent to close at $24.15 a share Thursday. The stock traded between $24.05 and $24.78 on volume of 1.48 million shares traded. Analysts at Leerink have recently downgraded the company’s rating to “market perform” and has also lowered its price target to $26.00. Shares of Santarus have gained approximately 120.0 percent year-to-date.
Find out more about Santarus including full access to the free equity report at:
Vanguard Health Systems, Inc. (NYSE: VHS) shares closed at $20.90 a share Thursday. The stock traded between $20.88 and $20.90 on volume of 215,683 shares traded. Analysts at RBC Capital have recently downgraded the company’s rating to “sector perform” from “outperform”.
Find out more about Vanguard Health Systems including full access to the free equity report at:
Exelis Inc. (NYSE: XLS) shares increased 2.81 percent to close at $15.00 a share Thursday. The stock traded between $14.75 and $15.09 on volume of 1.33 million shares traded. Analysts at RBC Capital have recently upgraded the company’s rating to “outperform” and have also raised its price target to $18.00. Shares of Exelis have gained approximately 360.0 percent year-to-date.
Find out more about Exelis including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...